An innovative bio-based platform for the cost-competitive production of L-Fucose, a building block for Human Milk Oligosaccharides (HMOs)

Informazioni relative al progetto

FucoPol

ID dell’accordo di sovvenzione: 736566

DOI

10.3030/736566

Progetto chiuso

Data della firma CE 29 Luglio 2016

Data di avvio 1 Agosto 2016

Data di completamento 30 Novembre 2016

Finanziato da

• SOCIETAL CHALLENGES - Food security, sustainable agriculture and forestry, marine, maritime and inland water research, and the bioeconomy

Costo totale

€ 71 429,00

Contributo UE

€ 50 000,00

Coordinato da

SETENTA E TRES MIL E CEM LDA
Portugal

Periodic Reporting for period 1 - FucoPol (An innovative bio-based platform for the cost-competitive production of L-Fucose, a building block for Human Milk Oligosaccharides (HMOs))

Periodo di rendicontazione: 2016-08-01 al 2016-11-30

Sintesi del contesto e degli obiettivi generali del progetto

Currently a large scale production of HMOs is not feasible due to the complexity and costs related to increasing availability of L-fucose. 73100 has developed and patented a novel bacterial biopolymer - FucoPol - as a natural source for the efficient and cost-competitive production of pure L-fucose. The main objective of the project is to demonstrate and validate the scalability of the platform, proving its usefulness for industrial-scale production.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

During the project, 73100 accomplished a full analysis of the technical and business potential of FucoPol – the innovative bio-based platform for the production of L-fucose. In Phase 1, 73100 determined exactly what capabilities would be required from third parties both for the project duration and full commercial rollout. Through an extensive search of potential partners to support the scale-up activities the company were able to confirm the availability of Biotrend and Cipan for the project. Both companies have strong industrial biotechnology expertise, state-of-the-art facilities and both are also located in Portugal.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

73100 is set to become the world’s first large scale L-fucose producer. Current technologies are hindered by the complexity and costs related to the attempt to increase the availability of the core component, L-fucose. The innovative technology – on which the FucoPol production is based – entails its use as a natural platform to generate pure carbohydrates (fucose, galactose, glucose and glucuronic acid), either in mixtures with defined composition or as individual monosaccharides. Depending on the application of L-fucose, 73100 has the potential to sell to several different customer types. 73100 have identified the most desired applications for FucoPol derived products, mainly L-fucose, and have identified companies engaged in chemical synthesis for HMO’s, manufacturing of prebiotic food/beverages, pharmaceuticals, and cosmetics. 73100 has the potential to first sell to chemical reagent distributors in Europe and North America. 73100 expects rapid growth once commercialized and increased profitability as their product is sold for new HMO applications (e.g. as a novel food ingredient). 73100 also has the potential to address relevant challenges faced by many European societies – mainly related to providing an adequate supply for high-quality food while enhancing innovation and sustainability in the production processes. In fact, glycoscience in Europe is fast becoming an essential part of modern innovative biotechnology and having access to state-of-the-art knowledge and technologies in this sector will provide the European bio-based industries with a strong competitive advantage on a worldwide stage.

73100.jpg